Patents by Inventor Katherine ST. LAURENT

Katherine ST. LAURENT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Calcium binding protein, spermatid specific 1, as a biomarker for diagnosis or treatment of stress
    Patent number: 10942174
    Abstract: A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: March 9, 2021
    Inventors: Dean Befus, Thomas Ritz, Chris St. Laurent, Katherine St. Laurent
  • CALCIUM BINDING PROTEIN, SPERMATID SPECIFIC 1, AS A BIOMARKER FOR DIAGNOSIS OR TREATMENT OF STRESS
    Publication number: 20190079082
    Abstract: A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Dean BEFUS, Thomas RITZ, Chris ST. LAURENT, Katherine ST. LAURENT